CoChat

Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Localized Benign Main Pancreatic Duct Stenosis Patients

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Background: This study aimed to evaluate and identify the specific CT findings by focusing on abnormalities in the main pancreatic duct (MPD) and pancreatic parenchyma in patients with small pancreatic cancer (PC) including carcinoma in situ (CIS). Methods: Nine CT findings indicating abnormalities of MPD and pancreatic parenchyma were selected as candidate findings for the presence of small PC ≤ 10 mm. The proportions of patients positive for each finding were compared between small PC and benign MPD stenosis groups. Interobserver agreement between two independent image reviewers was evaluated using kappa statistics. Results: The final analysis included 24 patients with small PC (including 11 CIS patients) and 28 patients with benign MPD stenosis. The proportion of patients exhibiting partial pancreatic parenchymal atrophy (PPA) corresponding to the distribution of MPD stenosis (45.8% vs. 7.1%, p < 0.01), upstream PPA arising from the site of MPD stenosis (33.3% vs. 3.6%, p = 0.01), and MPD abrupt stenosis (45.8% vs. 14.3%, p = 0.03) was significantly higher in the small PC group than in the benign MPD stenosis group. Conclusions: The presence of partial PPA, upstream PPA, and MPD abrupt stenosis on a CT image was highly suggestive of the presence of small PCs including CIS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/diagnostics10070445

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Illustrations of pancreatic parenchymal atrophy (PPA). PPA was categorized into partial PPA or upstream PPA. (A); Partial PPA was defined as an atrophic change corresponding to the distribution of main pancreatic duct (MPD) stenosis (red arrow heads). (B); Upstream PPA was defined as atrophic change of the whole upstream side of the parenchyma arising from the site of MPD stenosis (red arrow). (C); Non-atrophic parenchyma was defined as the absence of parenchymal atrophic change in the whole parenchyma despite the presence of main pancreatic duct stenosis.
Figure 1 Illustrations of pancreatic parenchymal atrophy (PPA). PPA was categorized into partial PPA or upstream PPA. (A); Partial PPA was defined as an atrophic change corresponding to the distribution of main pancreatic duct (MPD) stenosis (red arrow heads). (B); Upstream PPA was defined as atrophic change of the whole upstream side of the parenchyma arising from the site of MPD stenosis (red arrow). (C); Non-atrophic parenchyma was defined as the absence of parenchymal atrophic change in the whole parenchyma despite the presence of main pancreatic duct stenosis.CC BY · PubMed Central
Figure 2 Definition of pancreatic parenchymal atrophy. (A); Partial pancreatic parenchymal atrophy (PPA) was defined when parameters obtained in CT met the following three criteria. First, a partial invagination of the pancreas parenchyma exhibited a width from the MPD wall of 4 mm or less (W1). Second, the length of the partial PPA ranged from 10 to 25 mm (L1). Third, the width of upstream side of parenchyma was more than 6 mm (W2). (B); Upstream PPA was defined as an overall upstream parenchymal atrophy with 4 mm or less in the width of stenosis site (W1) and upstream side (W3) of parenchyma.
Figure 2 Definition of pancreatic parenchymal atrophy. (A); Partial pancreatic parenchymal atrophy (PPA) was defined when parameters obtained in CT met the following three criteria. First, a partial invagination of the pancreas parenchyma exhibited a width from the MPD wall of 4 mm or less (W1). Second, the length of the partial PPA ranged from 10 to 25 mm (L1). Third, the width of upstream side of parenchyma was more than 6 mm (W2). (B); Upstream PPA was defined as an overall upstream parenchymal atrophy with 4 mm or less in the width of stenosis site (W1) and upstream side (W3) of parenchyma.CC BY · PubMed Central
Figure 3 Flow-chart of the inclusion of patients in the small pancreatic cancer group. * Carcinoma in situ.
Figure 3 Flow-chart of the inclusion of patients in the small pancreatic cancer group. * Carcinoma in situ.CC BY · PubMed Central
Figure 4 Flow-chart of the inclusion of patients in the benign main pancreatic duct stenosis group. AIP: autoimmune pancreatitis; CE-CT: contrast-enhanced computed tomography.
Figure 4 Flow-chart of the inclusion of patients in the benign main pancreatic duct stenosis group. AIP: autoimmune pancreatitis; CE-CT: contrast-enhanced computed tomography.CC BY · PubMed Central
Figure 5 The proportions of patients exhibiting computed tomography findings in the small pancreatic cancer and benign main pancreatic stenosis groups. * Overall PPA was defined as the combination of partial and upstream PPA.
Figure 5 The proportions of patients exhibiting computed tomography findings in the small pancreatic cancer and benign main pancreatic stenosis groups. * Overall PPA was defined as the combination of partial and upstream PPA.CC BY · PubMed Central
Figure 6 Typical computed tomography (CT) images showing partial pancreatic parenchymal atrophy (PPA) in an 81-year-old man with stage 0 (carcinoma in situ) pancreatic cancer. Localized main pancreatic duct (MPD) stenosis without tumor lesion in the pancreatic body was detected in CT for further examination of a small cyst in the pancreatic tail. (A); The area exhibiting PPA had an atrophic change corresponding to the distribution of MPD stenosis (yellow arrow head) and defined as localized atrophy compared with the upstream and downstream parenchyma (pink arrow). (B); Hematoxylin and eosin (H&E)-stained resected specimen. Histopathological examination showed high-grade pancreatic intraepithelial neoplasia (PanIN) of the main pancreatic duct (H&E stain, ×20 magnification). (C); Severe atrophy and fibrosis of the pancreatic parenchyma and focal fatty change adjacent to the high-grade PanIN (H&E stain, ×0.5 magnification). (D); Downstream side of pancreatic parenchyma had no atrophic change as compared with Figure 6C (H&E stain, ×0.5 magnification). (E); Upstream side of pancreatic parenchyma had slight fibrosis and focal fatty change as compared with Figure 6C. Acinar cell architecture was maintained (H&E stain, ×1 magnification).
Figure 6 Typical computed tomography (CT) images showing partial pancreatic parenchymal atrophy (PPA) in an 81-year-old man with stage 0 (carcinoma in situ) pancreatic cancer. Localized main pancreatic duct (MPD) stenosis without tumor lesion in the pancreatic body was detected in CT for further examination of a small cyst in the pancreatic tail. (A); The area exhibiting PPA had an atrophic change corresponding to the distribution of MPD stenosis (yellow arrow head) and defined as localized atrophy compared with the upstream and downstream parenchyma (pink arrow). (B); Hematoxylin and eosin (H&E)-stained resected specimen. Histopathological examination showed high-grade pancreatic intraepithelial neoplasia (PanIN) of the main pancreatic duct (H&E stain, ×20 magnification). (C); Severe atrophy and fibrosis of the pancreatic parenchyma and focal fatty change adjacent to the high-grade PanIN (H&E stain, ×0.5 magnification). (D); Downstream side of pancreatic parenchyma had no atrophic change as compared with Figure 6C (H&E stain, ×0.5 magnification). (E); Upstream side of pancreatic parenchyma had slight fibrosis and focal fatty change as compared with Figure 6C. Acinar cell architecture was maintained (H&E stain, ×1 magnification).CC BY · PubMed Central
Figure 7 Typical computed tomography (CT) images showing upstream pancreatic parenchymal atrophy in a 72-year-old man with stage IA (tumor diameter of 10 mm in size) pancreatic cancer. Localized main pancreatic duct dilation was detected in the pancreatic body in the CT after the recurrence of acute pancreatitis and tumor lesion was detected in endoscopic ultrasonography. (A); Typical CT images showing upstream pancreatic parenchymal atrophy (PPA). The area exhibiting PPA has an atrophic change in the whole upstream side of the lesion (yellow arrow heads). (B); Hematoxylin and eosin (H&E)-stained resected specimen shows cancer nodule with a diameter of 10 mm in size (H&E stain, ×0.5 magnification). (C); Severe atrophy of pancreatic parenchyma and fatty change were observed in the upstream section from cancer nodule (H&E stain, ×0.5 magnification).
Figure 7 Typical computed tomography (CT) images showing upstream pancreatic parenchymal atrophy in a 72-year-old man with stage IA (tumor diameter of 10 mm in size) pancreatic cancer. Localized main pancreatic duct dilation was detected in the pancreatic body in the CT after the recurrence of acute pancreatitis and tumor lesion was detected in endoscopic ultrasonography. (A); Typical CT images showing upstream pancreatic parenchymal atrophy (PPA). The area exhibiting PPA has an atrophic change in the whole upstream side of the lesion (yellow arrow heads). (B); Hematoxylin and eosin (H&E)-stained resected specimen shows cancer nodule with a diameter of 10 mm in size (H&E stain, ×0.5 magnification). (C); Severe atrophy of pancreatic parenchyma and fatty change were observed in the upstream section from cancer nodule (H&E stain, ×0.5 magnification).CC BY · PubMed Central
Figure 8 Typical computed tomography (CT) images showing non-atrophic parenchyma in a 55-year-old man with benign main pancreatic duct (MPD) stenosis. Localized MPD stenosis without tumor lesion was detected in the pancreatic body in CT after the recurrence of acute pancreatitis. (A); Typical CT images showing non-atrophic parenchyma. Non-atrophic parenchyma in a patient with chronic pancreatitis diagnosed in the resected specimen. CT image shows no evidence of pancreatic parenchymal atrophy regardless of the presence of isolated MPD stenosis (green arrow). (B); Hematoxylin and eosin (H&E)-stained resected specimen in the section of MPD stenosis area. Histopathological examination showed that acinar cell architecture was maintained (H&E stain, ×0.5 magnification). (C); Slight fibrosis and focal fatty change without parenchymal atrophy were observed in the pancreatic tissues surrounding stenosis MPD (H&E stain, ×4 magnification).
Figure 8 Typical computed tomography (CT) images showing non-atrophic parenchyma in a 55-year-old man with benign main pancreatic duct (MPD) stenosis. Localized MPD stenosis without tumor lesion was detected in the pancreatic body in CT after the recurrence of acute pancreatitis. (A); Typical CT images showing non-atrophic parenchyma. Non-atrophic parenchyma in a patient with chronic pancreatitis diagnosed in the resected specimen. CT image shows no evidence of pancreatic parenchymal atrophy regardless of the presence of isolated MPD stenosis (green arrow). (B); Hematoxylin and eosin (H&E)-stained resected specimen in the section of MPD stenosis area. Histopathological examination showed that acinar cell architecture was maintained (H&E stain, ×0.5 magnification). (C); Slight fibrosis and focal fatty change without parenchymal atrophy were observed in the pancreatic tissues surrounding stenosis MPD (H&E stain, ×4 magnification).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. Zaheer, 2014, Differentiating autoimmune pancreatitis from pancreatic adenocarcinoma using dual-phase computed tomography, J. Comput. Assist. Tomogr., 38, 146

Cited by

See all 66

Metadata

Authors
Yamao, K., Takenaka, M., Ishikawa, R., Okamoto, A., Yamazaki, T., Nakai, A., Omoto, S., Kamata, K., Minaga, K., Matsumoto, I., Takeyama, Y., Numoto, I., Tsurusaki, M., Chikugo, T., Chiba, Y., Watanabe, T., & Kudo, M.
Affiliations
Kindai University (JP)
Corresponding author
Yamao, Kentaro
Venue
Diagnostics
Publisher
MDPI AG
Published
2020-07-01
Volume
10
Issue
7
Pages
445
ISSN
2075-4418 (ISSN-L)
OpenAlex
W3038994021
Cited by
58
References
35
Citations by year
2026: 12 · 2025: 10 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 8
FWCI
2.26
Type
journal article
Language
en
Open access
Locations
  • Diagnostics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Keywords
small pancreatic cancer, carcinoma in situ, main pancreatic duct stenosis, computed tomography findings, diagnostic specificity, interobserver agreement

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Localized Benign Main Pancreatic Duct Stenosis Patients. https://app.cochat.ai/papers/10.3390/diagnostics10070445
The paper
Yamao, K., Takenaka, M., Ishikawa, R., Okamoto, A., Yamazaki, T., Nakai, A., Omoto, S., Kamata, K., Minaga, K., Matsumoto, I., Takeyama, Y., Numoto, I., Tsurusaki, M., Chikugo, T., Chiba, Y., Watanabe, T., & Kudo, M. (2020). Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Localized Benign Main Pancreatic Duct Stenosis Patients. Diagnostics. https://doi.org/10.3390/diagnostics10070445

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.